Difficulty: Medium
Average Score: 83%
Practice
The drug that is LEAST effective for the treatment of chronic renal disease occurring in 1-2% of children with Henoch-Schonlein purpura (HSP) is
Correct answer
A
Rationale
In the context of pediatric nursing and the treatment of chronic renal disease in children with Henoch-Schonlein purpura (HSP), the correct answer, A) prednisolone, is the least effective option among the listed medications. Prednisolone is a corticosteroid commonly used to reduce inflammation and suppress the immune system's response. While it may be effective in managing acute symptoms of HSP, it is less effective in treating chronic renal disease associated with HSP.
Option B) azathioprine is an immunosuppressive medication that is sometimes used in the treatment of autoimmune conditions but may have potential side effects on the kidneys, making it a less preferable choice for chronic renal disease in this context.
Option C) cyclophosphamide is a potent immunosuppressive and cytotoxic agent that can have severe side effects, including renal toxicity, which would make it a risky choice for treating renal disease in children with HSP.
Option D) cyclosporine is another immunosuppressive drug that can be used in various autoimmune conditions, but it also has potential nephrotoxic effects, which could worsen the renal condition in children with HSP.
In an educational context, it is crucial for pediatric nurses to understand the appropriate pharmacological management of chronic renal disease in children with underlying conditions like HSP. Prednisolone, while commonly used in HSP treatment, may not be the most effective option for managing chronic renal complications. Nurses need to be aware of the potential side effects and limitations of different medications to provide safe and effective care to pediatric patients with complex conditions like HSP.
Option B) azathioprine is an immunosuppressive medication that is sometimes used in the treatment of autoimmune conditions but may have potential side effects on the kidneys, making it a less preferable choice for chronic renal disease in this context.
Option C) cyclophosphamide is a potent immunosuppressive and cytotoxic agent that can have severe side effects, including renal toxicity, which would make it a risky choice for treating renal disease in children with HSP.
Option D) cyclosporine is another immunosuppressive drug that can be used in various autoimmune conditions, but it also has potential nephrotoxic effects, which could worsen the renal condition in children with HSP.
In an educational context, it is crucial for pediatric nurses to understand the appropriate pharmacological management of chronic renal disease in children with underlying conditions like HSP. Prednisolone, while commonly used in HSP treatment, may not be the most effective option for managing chronic renal complications. Nurses need to be aware of the potential side effects and limitations of different medications to provide safe and effective care to pediatric patients with complex conditions like HSP.